Navigation Links
Stereotaxis Reports 19% Second Quarter Revenue Growth

ST. LOUIS, Aug. 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today reported improved financial results for the second quarter ended June 30, 2009. Revenue for the recent second quarter totaled $12.6 million, an increase of 19% over the $10.7 million reported for the second quarter of 2008. During the quarter, the Company recognized revenue on eight Niobe(R) Magnetic Navigation Systems and two Odyssey(TM) systems totaling $8.2 million, while disposables, services and accessories revenue was a record $4.5 million, a 62% increase from the same period in 2008. Within recurring revenue, disposable revenue associated with utilization increased over 10% from the first quarter of 2009. The Company's operating expenses fell to $14.6 million, a decrease of 22% from the second quarter of 2008.

For the first six months of 2009, revenue grew 34% to $23.8 million compared with $17.7 million in the first half of 2008. Gross margin increased 41% from $11.1 million to $15.7 million in the 2009 six month period. Operating expenses declined 19%, resulting in a 46% reduction in the operating loss to $13.8 million for the first six months of 2009 compared with $25.4 million in the same period in 2008.

Michael P. Kaminski, President and Chief Executive Officer, said, "EP labs and hospitals are recognizing the tremendous value we bring to the institution, the physician and the patient despite the challenging economic environment. During the first half of the year we generated strong revenue growth, reflecting an increase in installations as well as higher recurring revenue driven by the commercial introduction of the magnetic irrigated catheter. And we've continued to drive operating expenses lower. Finally, we have introduced four new products in the first half of the year and expect several more in the balance of the year which demonstrates our commitment to strengthening our value in electrophysiology."

"The rollout of the magnetic irrigated catheter in the U.S. and Europe is proceeding well. We anticipate a steady increase in utilization over time as sites gain more experience with its use and clinical results remain very positive. As we have stated, we completed the roll-out of the magnetic irrigated catheter in Europe. To date, we have introduced the catheter at 51 of the 70 sites in the U.S. We are on target to complete the U.S. roll-out by the end of this year and expect to see year over year growth in utilization in the U.S.," said Mr. Kaminski.

"Interest in the Odyssey and Cinema systems remains strong. We believe there is a substantial opportunity for sales of Odyssey to electrophysiologists who do not have a Niobe system, and we are actively pursuing these potential customers.

"New capital orders for the quarter were $5 million. Our expectations are that our backlog, which totaled $42 million for orders we expect to convert to revenue in the next 18 months, should help insulate us from a weaker short term order rate and provide the foundation for us to grow in the next 18 months. We continue to expect 2009 revenue to exceed 2008 revenue, and we are focused on driving as much of that as possible to the bottom line, resulting in a significantly improved financial performance for the Company," Mr. Kaminski concluded.

Second Quarter 2009 Financial Performance

Gross margin for the quarter was $8.0 million, or 63% of revenue, compared with $6.5 million, or 61% of revenue in the second quarter of 2008. Included in the margin in the recent second quarter were approximately $400,000 in one time service costs.

Second quarter operating expenses decreased 22% to $14.6 million from $18.7 million in the second quarter of 2008. Included in the recent second quarter was a $535,000 charge to write-off unusable assets.

The Company reported a net loss for the second quarter of 2009 of $7.4 million, or $(0.18) per share. This compares with a net loss for the second quarter of 2008 of $12.8 million, or $(0.35) per share. The weighted average shares for the recent second quarter totaled 41.7 million compared with 36.5 million in the second quarter of last year. The increase was due in large part to the issuance of 4.4 million shares as part of two concurrent private placements of stock completed in December 2008.

Cash used in operations was $5.6 million for the second quarter of 2009 compared with $7.3 million in the second quarter of 2008. Cash and equivalents at June 30, 2009 totaled $12.8 million, compared with $30.4 million at December 31, 2008. Total debt was $28.4 million, including $13.2 million drawn against the Company's $25 million line of credit.

2009 Financial Guidance

The Company updated its outlook for 2009 as follows:

  • Revenue for 2009 is expected to exceed revenue for 2008, with growth being driven by Niobe backlog conversion, Odyssey revenue and an increase of more than 50% in recurring revenue.
  • Gross margins above 65%.
  • Operating expenses below the 2008 level of $67.2 million, with sales and marketing expenses at or above the $28.7 million level of 2008 and R&D and G&A below the $17.4 million and $21.1 million, respectively, in 2008.

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Time today to discuss its financial results for the second quarter. To access the conference call, please dial (877) 941-2333. International participants can call (480) 629-9724. An audio replay of the call will be available for seven days following the call at (800) 406-7325 for U.S. callers or (303) 590-3030 for those calling outside the U.S. The password required to access the replay is 4110443#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

                                     STEREOTAXIS, INC.
                                 STATEMENTS OF OPERATIONS

                            Three Months Ended          Six Months Ended
                                 June 30,                    June 30,
                                 --------                    --------
                            2009          2008          2009          2008
                            ----          ----          ----          ----
       System         $8,162,504    $7,898,310   $15,023,312   $12,275,707
        service and
        accessories    4,481,833     2,760,282     8,754,162     5,411,335
                       ---------     ---------     ---------     ---------
    Total revenue     12,644,337    10,658,592    23,777,474    17,687,042

    Cost of revenue
       System          3,212,031     3,868,166     5,775,513     5,724,268
        service and
        accessories    1,453,854       314,471     2,351,052       884,431
                       ---------       -------     ---------       -------
    Total cost of
     revenue           4,665,885     4,182,637     8,126,565     6,608,699

    Gross margin       7,978,452     6,475,955    15,650,909    11,078,343

    Operating expenses:
       Research and
        development    3,636,007     4,782,074     6,945,870     9,480,871
       Sales and
        marketing      7,680,549     8,621,028    15,133,984    16,284,739
       General and
        administration 3,314,678     5,262,213     7,352,843    10,738,335
                       ---------     ---------     ---------    ----------
     expenses         14,631,234    18,665,315    29,432,697    36,503,945
                      ----------    ----------    ----------    ----------
     loss             (6,652,782)  (12,189,360)  (13,781,788)  (25,425,602)
    Other income         304,709             -       555,646             -
     income                4,376        24,226        31,349       131,954
     expense          (1,096,080)     (624,527)   (1,775,071)   (1,027,178)
                      ----------      --------   -----------   -----------
    Net loss         $(7,439,777) $(12,789,661) $(14,969,864) $(26,320,826)
                    ============  ============  ============  ============

     Net loss per  common
        Basic and
         diluted          $(0.18)       $(0.35)       $(0.36)       $(0.72)
                          ======        ======        ======        ======

    Weighted average
     shares used
     in computing
     net loss per
     common share:
      Basic and
       diluted        41,670,130    36,523,194    41,476,704    36,507,915
                      ==========    ==========    ==========    ==========

                                      STEREOTAXIS, INC.
                                        BALANCE SHEETS

                                                      June 30,    December 31,
                                                       2009            2008
                                                       ----            ----
    Current Assets:
       Cash and cash equivalents                    $12,779,581   $30,355,657
       Short-term investments
       Accounts receivable, net of allowance
        of $200,364 and $328,307 in 2009 and
        2008, respectively                           11,951,238     9,739,008
       Current portion of long-term
        receivables                                     197,912       197,351
       Inventories                                    7,458,777     8,086,956
       Prepaid expenses and other current
        assets                                        4,184,150     2,966,510
                                                      ---------     ---------
    Total current assets                             36,571,658    51,345,482
    Property and equipment, net                       5,818,582     6,420,600
    Intangible assets                                 1,211,111     1,277,778
    Long-term receivables                               284,119       298,123
    Other assets                                         24,632        98,382
                                                         ------        ------
    Total assets                                    $43,910,102   $59,440,365
                                                    ===========   ===========

    Liabilities and stockholders' equity
    Current liabilities:
       Current maturities of long-term debt         $14,901,491    $3,901,491
       Accounts payable                               4,279,511     4,561,928
       Accrued liabilities                            8,157,417     9,873,818
       Deferred contract revenue                      8,108,174     9,676,339
       Warrants                                       4,498,945             -
                                                      ---------     ---------
    Total current liabilities                        39,945,538    28,013,576

    Long term debt, less current maturities          13,496,487    25,271,547
    Long term deferred contract revenue                 823,616     1,225,656
    Other liabilities                                   147,317       158,905

    Stockholders' equity:
       Preferred stock, par value $0.001;
        10,000,000 shares authorized at 2009 and
        2008; none outstanding at 2009 and 2008               -             -
       Common stock, par value $0.001;
        100,000,000 shares authorized at 2009 and
        2008; 42,747,838 and 42,049,792 issued
        at 2009 and 2008, respectively                   42,748        42,050
       Additional paid-in capital                   300,588,586   300,892,957
       Treasury stock, 40,151 shares at 2009
        and 2008                                       (205,999)     (205,999)
       Accumulated deficit                         (310,928,191) (295,958,327)
                                                   ------------  ------------
    Total stockholders' equity                      (10,502,856)    4,770,681
                                                    -----------     ---------
    Total liabilities and stockholders'
     equity                                         $43,910,102   $59,440,365
                                                    ===========   ===========

SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Receives $20 Million in Additional Loan Commitments
6. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
7. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
8. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
9. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
10. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. Stereotaxis Reports Record First Quarter Orders
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
Breaking Medicine Technology: